Advisory
Official notices and statements regarding BF-7® authenticity, intellectual property rights, and scientific integrity.
Verification of BF-7® Authenticity and Intellectual Property Rights
Addresses unauthorized association of products such as "Cera-Q" and "Memo-Q" with the BF-7® brand. Includes USPTO trademark cancellation decision (March 2022), FDA NDI #1041 status, MFDS individual recognition (2009-46), and 25 years of clinical research evidence.
BF-7® Trademark Clarification: The 2018 Nutrients Study
Corrects the 2018 Nutrients study (Kang et al.), which misattributes BF-7® as a material supplied by BrainOn and sold as "Cera-Q." Confirms BF-7® as Famenity’s exclusive trademark with no supply-chain relationship to BrainOn, Cera-Q, or Memo-Q. Includes the NIH PMC link to the original article.
BF-7® Intellectual Property & Literature Protection Notice
Addresses unauthorized use of the BRAINFACTOR-7® / BF-7® trademarks and misappropriation of Famenity’s clinical literature in sponsored media (PricePlow) and third-party product pages (Natrol Cognium). Clarifies that BF-7® studies belong exclusively to Famenity and that Cera-Q, Memo-Q, and Cognium are not the same as BF-7®.
